Stockscreener 앱 받기
21.82
0.84%
-0.1849
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Aug Retail: Does Apellis Pharmaceuticals Inc stock have upside surprise potentialSell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy - Chartmill
Apellis Pharma CEO Francois sells $161,945 in stock By Investing.com - Investing.com Canada
Apellis Pharma VP Chopas sells $14k in shares By Investing.com - Investing.com Canada
Apellis Pharma CMO Baumal sells $37k in shares - Investing.com
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock - Investing.com
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells 8,182 Shares of Stock - MarketBeat
James George Chopas Sells 726 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 909 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 1,882 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 2,475 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 2,892 Shares of Stock - MarketBeat
Bank of America Upgrades Apellis Pharmaceuticals (APLS) Amid Suc - GuruFocus
Why Is Apellis Pharma Stock Gaining Wednesday?Apellis Pharmaceuticals (NASDAQ:APLS) - Benzinga
Bank of America Upgrades Apellis Pharmaceuticals to Buy, Highlights Strong Empaveli Launch - Intellectia AI
Apellis upgraded at BofA on Empaveli launch (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up After Analyst Upgrade - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded at Bank of America - MarketBeat
Apellis stock rating upgraded by BofA on Empaveli’s commercial potential - Investing.com Canada
APLS Receives Analyst Upgrade to 'Buy' with Maintained Price Tar - GuruFocus
Liquidity Mapping Around (APLS) Price Events - Stock Traders Daily
Wells Fargo Maintains Overweight Rating for APLS, Lowers Price T - GuruFocus
Wells Fargo & Company Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Paroxysmal Nocturnal Hemoglobinuria Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Alexion Pharma, Apellis Pharma, Hoffmann-La Roche, Novartis - Barchart.com
Campbell & CO Investment Adviser LLC Invests $1.21 Million in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis stock crashes 23% in a week: Here's what you should know - MSN
Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases - MSN
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - Yahoo Finance
Market Trends: Does Apellis Pharmaceuticals Inc stock have upside surprise potential2025 Stock Rankings & Capital Efficient Trading Techniques - baoquankhu1.vn
Apellis stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada
Apellis Pharma VP Chopas sells $19k in shares By Investing.com - Investing.com Canada
Apellis Pharma chief business officer sells $39k in APLS stock - Investing.com Canada
Mark Jeffrey Delong Sells 1,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells $19,371.87 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 3,856 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 2,618 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells $226,027.34 in Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Pascal Deschatelets Sells 2,277 Shares - MarketBeat
David Watson Sells 5,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharma CFO Sullivan sells $85,553 in shares By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $128k in shares By Investing.com - Investing.com Canada
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Press Telegram - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 5.8% on Analyst Downgrade - MarketBeat
Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - sharewise.com
Assessing Apellis Pharmaceuticals (APLS) Valuation After 2025 Revenue Update And Pipeline Progress - Sahm
Rising SYFOVRE Demand and Prefilled Syringe Plan Could Be A Game Changer For Apellis Pharmaceuticals (APLS) - Yahoo Finance
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
APLS: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
Cantor Fitzgerald Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $35.00 - MarketBeat
Forecasting The Future: 9 Analyst Projections For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $28.00 by Analysts at Needham & Company LLC - MarketBeat
Needham lowers Apellis Pharmaceuticals stock price target on Syfovre concerns - Investing.com UK
Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
APLS: Needham Maintains Buy Rating, Lowers Price Target to $28 | - GuruFocus
Why Apellis Pharmaceuticals Wilted on Wednesday - MSN
A Look At Apellis Pharmaceuticals (APLS) Valuation After Strong 2025 Revenue Update And Nephrology Expansion - Yahoo Finance
Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Strategic Updates - TradingView — Track All Markets
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownHere's What Happened - MarketBeat
Apellis Pharmaceuticals (APLS) Is Up 9.8% After Strong SYFOVRE Demand Lifts Preliminary 2025 Revenues - Sahm
Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference - MarketBeat
Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference - TechStock²
Goldman Sachs reiterates Sell rating on Apellis stock amid revenue miss - Investing.com Canada
Apellis (APLS) Shares Plummet Over 17% - GuruFocus
Apellis Pharmaceuticals Reports Preliminary 2025 Revenues of $689 Million, Highlights Growth in SYFOVRE and EMPAVELI Sales - Quiver Quantitative
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Apellis Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
SG Americas Securities LLC Purchases 372,289 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
4.38%
1.95%
자본화:
|
볼륨(24시간):